La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cantargia Croissance future

Future contrôle des critères 2/6

Cantargia devrait augmenter ses bénéfices et ses revenus de 31.7% et de 40.7% par an respectivement, tandis que le BPA devrait croître de diminuer de 16.1% par an.

Informations clés

25.4%

Taux de croissance des bénéfices

-0.3%

Taux de croissance du BPA

Biotechs croissance des bénéfices	46.4%
Taux de croissance des recettes	40.7%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	02 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

May 31

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

May 02

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Jan 10

We Think Cantargia (STO:CANTA) Can Easily Afford To Drive Business Growth

Sep 20

Prévisions de croissance des bénéfices et des revenus

OM:CANTA - Estimations futures des analystes et données financières antérieures (SEK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-161	-163	-171	2
12/31/2025	289	-66	-147	102	2
12/31/2024	N/A	-165	-207	-187	2
6/30/2024	N/A	-228	-234	-234	N/A
3/31/2024	N/A	-241	-267	-267	N/A
12/31/2023	N/A	-280	-287	-287	N/A
9/30/2023	N/A	-299	-299	-292	N/A
6/30/2023	N/A	-293	-295	-287	N/A
3/31/2023	N/A	-330	-320	-313	N/A
12/31/2022	N/A	-372	-366	-359	N/A
9/30/2022	N/A	-385	-387	-387	N/A
6/30/2022	N/A	-419	-419	-419	N/A
3/31/2022	N/A	-411	-406	-406	N/A
12/31/2021	N/A	-367	-347	-346	N/A
9/30/2021	N/A	-319	-302	-301	N/A
6/30/2021	N/A	-255	-231	-230	N/A
3/31/2021	N/A	-206	-187	-186	N/A
12/31/2020	N/A	-173	-165	-156	N/A
9/30/2020	N/A	-153	-165	-149	N/A
6/30/2020	N/A	-139	-151	-135	N/A
3/31/2020	N/A	-127	-144	-129	N/A
12/31/2019	N/A	-111	-118	-111	N/A
9/30/2019	N/A	-102	-97	-97	N/A
6/30/2019	N/A	-98	-92	-92	N/A
3/31/2019	N/A	-101	-88	-88	N/A
12/31/2018	N/A	-91	-105	-105	N/A
9/30/2018	N/A	-78	-72	-72	N/A
6/30/2018	N/A	-68	-65	-65	N/A
3/31/2018	N/A	-56	N/A	-54	N/A
12/31/2017	N/A	-60	N/A	-41	N/A
9/30/2017	N/A	-65	N/A	-69	N/A
6/30/2017	N/A	-66	N/A	-64	N/A
3/31/2017	N/A	-58	N/A	-54	N/A
12/31/2016	N/A	-47	N/A	-42	N/A
9/30/2016	N/A	-34	N/A	-26	N/A
6/30/2016	N/A	-24	N/A	-21	N/A
3/31/2016	N/A	-22	N/A	-19	N/A
12/31/2015	N/A	-17	N/A	-30	N/A
9/30/2015	N/A	-15	N/A	-35	N/A
6/30/2015	N/A	-14	N/A	-13	N/A
3/31/2015	N/A	-10	N/A	-10	N/A
12/31/2014	N/A	-8	N/A	7	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CANTA devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CANTA devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CANTA devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CANTA ( 40.7% par an) devrait croître plus rapidement que le marché Swedish ( 1% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CANTA ( 40.7% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CANTA devrait être élevé dans 3 ans

Cantargia Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Forecast to breakeven in 2026

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

No longer forecast to breakeven

Price target decreased to kr22.00

Forecast breakeven date pushed back to 2024

Recent updates

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Can Cantargia (STO:CANTA) Afford To Invest In Growth?

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

New minor risk - Share price stability

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Chief Executive Officer recently bought kr104k worth of stock

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Chief Executive Officer recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

New major risk - Financial position

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

New minor risk - Share price stability

Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Chief Executive Officer recently bought kr140k worth of stock

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Price target decreased to kr22.00

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy

Cantargia Reports Preclinical Data Demonstrating Unique Treatment Effects of nadunolimab on Pancreatic Cancer Stromal Cells

Cantargia AB (Publ) Publishes Preclinical Data on Strong Anti-Tumor Efficacy of Nadunolimab in Combination with Chemotherapy

Cantargia Reports New Positive Preclinical Efficacy Data for CAN10 Supporting Development in Myocarditis

Cantargia Receives USPTO Notice of Allowance for Composition of Matter Patent on Antibody CAN10

Cantargia AB (Publ) Announces Executive Changes

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

Cantargia Announces ASCO 2022 Presentation Strengthens Positive Phase IIa interim results for nadunolimab in NSCLC

Cantargia AB (publ) Presents Clinical Interim Results At ASCO 2022 Highlighting the Potential of Nadunolimab in Combination with Checkpoint Inhibitor

Cantargia AB (publ) Reports Positive Preclinical Effects in Atherosclerosis Demonstrating Potential of Can10 in Cardiovascular Disease

Forecast breakeven date pushed back to 2024